Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1AFAMELANOTIDE1件: Afamelanotide2件: Afamelanotide ,
Afamelanotide acetate 💬
1件: MC1R 💬 3件: Hormone signaling, Melanogenesis, Neuroactive ligand-receptor interaction 💬2件: 159, 254 💬
2Afamelanotide (16 mg implant)1件: Afamelanotide2件: Afamelanotide ,
Afamelanotide acetate 💬
1件: MC1R 💬 3件: Hormone signaling, Melanogenesis, Neuroactive ligand-receptor interaction 💬1件: 159 💬
3Biospecimen Collection----18件: 13, 26, 28, 34, 46, 49, 50, 51, 53, 60, 62, 65, 96, 97, 159, 284, 285, 286 💬
4Ipilimumab1件: Ipilimumab1件: Ipilimumab 💬 1件: CTLA4 💬 4件: Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Rheumatoid arthritis, T cell receptor signaling pathway 💬9件: 13, 46, 49, 50, 51, 53, 96, 97, 159 💬
5Isotretinoin1件: Isotretinoin1件: Isotretinoin 💬 2件: RARA,
RARB 💬
8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬4件: 36, 39, 159, 160 💬
6Liposomal T4N5 lotion----1件: 159 💬
7Melatonin1件: Melatonin1件: Melatonin 💬 2件: MTNR1A,
MTNR1B 💬
2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬18件: 2, 6, 8, 13, 37, 46, 49, 72, 78, 86, 90, 96, 97, 145, 149, 159, 202, 265 💬
8Nivolumab1件: Nivolumab1件: Nivolumab 💬 1件: PDCD1 💬 3件: Cell adhesion molecule (CAM) interaction, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway 💬12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
9SCENESSE----3件: 159, 161, 254 💬
10TRABECTEDINA----1件: 159 💬
11Trabectedine----1件: 159 💬
12YONDELIS 0,25 mg polvo para concentrado para solución para perfusión----1件: 159 💬
13Yondelis 0.25 mg powder for concentrate for solution for infusion.----1件: 159 💬
14YONDELIS 1 mg polvo para concentrado para solución para perfusión----1件: 159 💬
15Yondelis 1 mg powder for concentrate for solution for infusion.----1件: 159 💬